Tehran University of Medical Sciences Iranian Journal of Public Health 2251-6085 52 11 2023 10 29 2412 2416 Yuyang Zhang The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fu-shun, Liaoning Province 113008, China Lili Sun The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fu-shun, Liaoning Province 113008, China Tieshuang Chen The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fu-shun, Liaoning Province 113008, China Yuanyuan Yue The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fu-shun, Liaoning Province 113008, China Lin Zhao The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fu-shun, Liaoning Province 113008, China Dan Zhang Department of Gynecology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun, Liao-ning Province 113008, China 2023 03 22 2023 10 29 Background: Ovarian cancer is one of the most common malignant tumors in Gynecology, whose treatment was seriously limited by the unclear understanding of molecular mechanism in disease development. LncRNA FGFR3-AS1 is involved in human cancers. In this study, we aimed to clarify its regulatory effect on ovarian cancer. Methods: Ovarian cell model was used in 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide (MTT) assay and flow cytometry for investigating the role of LncRNA FGFR3-AS1 in ovarian cancer. Western blot detection (CCND1、CDK6、MAPK9 and PIK3CA) tumor regulatory proteins. The study was conducted between March 2020 and October 2022 at General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, China. Results: The results demonstrated the upregulation of LncRNA FGFR3-AS1 in ovarian cancer, whose expression was positively related to tumor grade and AJCC stage, and negatively correlated with patients’ prognosis. LncRNA FGFR3-AS1 promoted ovarian cancer development through promoting cell growth and inhibiting cell apoptosis. PI3K signaling pathway-related proteins may be implicated in the LncRNA FGFR3-AS1 induced regulation of ovarian cancer. Conclusion: LncRNA FGFR3-AS1 was involved in the development of ovarian cancer, which has the potential to become therapeutic target and prognostic indicator in ovarian cancer treatment.   https://ijph.tums.ac.ir/index.php/ijph/article/view/31532 https://ijph.tums.ac.ir/index.php/ijph/article/download/31532/8092